Graves' disease hyperthyroidism medical therapy

Jump to navigation Jump to search

Graves' disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Graves' disease from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Approach

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Hyperthyroidism
Ophtalmopathy
Dermopathy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Graves' disease hyperthyroidism medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Graves' disease hyperthyroidism medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Graves' disease hyperthyroidism medical therapy

CDC on Graves' disease hyperthyroidism medical therapy

Graves' disease hyperthyroidism medical therapy in the news

Blogs on Graves' disease hyperthyroidism medical therapy

Directions to Hospitals Treating Graves' disease

Risk calculators and risk factors for Graves' disease hyperthyroidism medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1],Associate Editor(s)-in-Chief: Seyedmahdi Pahlavani, M.D. [2]

Overview

Antithyroid drugs are the first line treatment in Europe but ablation therapy either by thyroidectomy or radioactive iodine is more accepted in North America.

Hyperthyroidism Therapy

Genreral aspects

  • In a small proportion of patients, spontaneous remission occurs.
  • Smoking cessation is one of the mainstay of treatment.
  • Antithyroid drugs are the first line treatment in Europe.
  • Ablation therapy either by thyroidectomy or radioactive iodine is more accepted in North America.
  • Each treatment approach has advantages and drawbacks. The patient’s preference after receiving adequate counseling, remains a critical factor in therapy decisions.

The following table summarizes the medical therapy and surgical option for treatment.

Treatment Mechanism Route of administration Advantages Disadvantages Special considerations
Beta-blockers
  • Block β-adrenergic receptors;
  • propranolol may block conversion of T4 to T3
Oral; may be administered

intravenously in acute

cases

Ameliorates sweating, anxiety, tremulousness, palpitations, and tachycardia
  • Does not influence course of disease
  • Use cautiously in patients with asthma, CHF , bradyarrhythmias or Raynaud’s phenomenon
  • Use cardioselective beta-blockers, especially in patients with COPD
  • Use calcium-channel blockers as alternative
Antithyroid drugs (methimazole,

carbimazole, and propylthiouracil)

  • Methimazole, carbimazole, and propylthiouracil block thyroid peroxidase and thyroid hormone synthesis
  • propylthiouracil also blocks conversion of thyroxine to triiodothyronine
Given as either a single, high fixed dose (e.g., 10–30 mg of methimazole or 200–600 mg of propylthiouracil daily)

and adjusted as euthyroidism is achieved or combined with thyroxine to prevent hypothyroidism (“block–replace” regimen)

  • Outpatient therapy
  • Low risk of hypothyroidism
  • No radiation hazard or surgical risk
  • Remission rate 40–50%
  • High recurrence rate
  • Frequent testing required unless block-replacement therapy is used
  • Minor side effects in ≤5% of patients (rash, urticaria, arthralgia, fever, nausea, abnormalities of taste and smell)
Major side effect usually within first 3 mo of therapy
  • Agranulocytosis in <0.2% of patients
  • Hepatotoxicity in ≤0.1%
  • Cholestasis for the thionamides and hepatocellular necrosis for propylthiouracil
  • Antineutrophil cytoplasmic antibody–associated vasculitis in ≤0.1% of patients
Radioactive iodine

(iodine-131)

  • Irradiation causes thyroid cell damage and cell death
Oral; activity either fixed (e.g., 15 mCi [555 MBq]) or calculated on the basis of goiter size and uptake and turnover investigations
  • Normally outpatient procedure
  • Definitive therapy
  • Low cost
  • Few side effects
  • Effectively reduces goiter size
  • Potential radiation hazards
  • Adherence to a country’s particular radiation regulations
  • Radiation thyroiditis
  • Decreasing efficacy with increasing goiter size
  • Eventual hypothyroidism in most patients
  • Should not be used in patients with active thyroid ophthalmopathy
  • Contraindicated in women who are pregnant or breast-feeding and for 6 wk after breast-feeding has stopped
Thyroidectomy Most or all thyroid tissue is removed surgically -----
  • Rapid euthyroidism
  • Recurrence extremely rare
  • No radiation hazard,
  • Definitive histologic results
  • Rapid relief of pressure symptoms
  • Most expensive therapy
  • Hypothyroidism is the aim
  • Risks associated with surgery and anesthesiology
  • Minor complications in 1–2% of patients (bleeding, infection, scarring),
  • Major complications in 1–4% (hypoparathyroidism, recurrent laryngeal-nerve damage)
  • Does not influence course of Graves’ ophthalmopathy during pregnancy
  • Is best performed during the second trimester

Antithyroid Drugs

  • Methimazole, carbimazole and propylthiouracil are the available anti thyroid drugs.
  • Methimazole is preferred for initial therapy in both Europe and North America because of its favorable side-effect profile.[1][2]
  • Durable remission occurs in 40 to 50% of patients which is defined as euthroidism for at least 12 months following 1-2 years of treatment.
  • Patients may be switched from one drug to another when necessitated by minor side effects.
  • Monitoring by means of liver-function tests and white-cell counts before and during antithyroid drug therapy is advocated by some experts but is not currently supported by consensus opinion.

Radioactive Iodine

  • Radioactive iodine therapy offers relief from symptoms of hyperthyroidism within weeks.
  • Radioiodine is not associated with an increased risk of cancer.[3]
  • It can provoke or worsen ophthalmopathy.[4]

References

  1. Burch HB, Burman KD, Cooper DS (2012). "A 2011 survey of clinical practice patterns in the management of Graves' disease". J. Clin. Endocrinol. Metab. 97 (12): 4549–58. doi:10.1210/jc.2012-2802. PMID 23043191.
  2. Bartalena L, Burch HB, Burman KD, Kahaly GJ (2016). "A 2013 European survey of clinical practice patterns in the management of Graves' disease". Clin. Endocrinol. (Oxf). 84 (1): 115–20. doi:10.1111/cen.12688. PMID 25581877.
  3. Ron E, Doody MM, Becker DV, Brill AB, Curtis RE, Goldman MB, Harris BS, Hoffman DA, McConahey WM, Maxon HR, Preston-Martin S, Warshauer ME, Wong FL, Boice JD (1998). "Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group". JAMA. 280 (4): 347–55. PMID 9686552.
  4. Bartalena L, Tanda ML (2009). "Clinical practice. Graves' ophthalmopathy". N. Engl. J. Med. 360 (10): 994–1001. doi:10.1056/NEJMcp0806317. PMID 19264688.

Template:WH Template:WS